Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy
Triple-negative breast cancer (TNBC) is among the aggressive subtype of breast cancer with a distinct lack of viable treatment strategies and poor clinical outcomes. Anti-PD-1 chemoimmunotherapy (CIT), which leverages the vast array of immunomodulatory effects induced by chemotherapeutic agents to p...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2527303 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|